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ABSTRACT Protective immunity against preerythrocytic malaria parasite infection is difficult to achieve. Intracellular Plasmo-
dium parasites likely minimize antigen presentation by surface-expressed major histocompatibility complex class I (MHC-I)
molecules on infected cells, yet they actively remodel their host cells by export of parasite factors. Whether exported liver-stage
proteins constitute better candidates for MHC-I antigen presentation to CD8 T lymphocytes remains unknown. Here, we sys-
tematically characterized the contribution of protein export to the magnitude of antigen-specific T-cell responses against Plas-
modium berghei liver-stage parasites in C57BL/6 mice. We generated transgenic sporozoites that secrete a truncated ovalbumin
(OVA) surrogate antigen only in the presence of an amino-terminal protein export element. Immunization with live attenuated
transgenic sporozoites revealed that antigen export was not critical for CD8 T-cell priming but enhanced CD8 T-cell prolifer-
ation in the liver. Upon transfer of antigen-specific CD8 T cells, liver-stage parasites secreting the target protein were elimi-
nated more efficiently. We conclude that Plasmodium parasites strictly control protein export during liver infection to minimize
immune recognition. Strategies that enhance the discharge of parasite proteins into infected hepatocytes could improve the effi-
cacy of candidate preerythrocytic malaria vaccines.
IMPORTANCE Vaccine development against Plasmodium parasites remains a priority in malaria research. The most advanced ma-
laria subunit vaccine candidates contain Plasmodium surface proteins with important roles for parasite vital functions. A funda-
mental question is whether recognition by effector CD8 T cells is restricted to sporozoite surface antigens or extends to parasite
proteins that are synthesized during the extensive parasite expansion phase in the liver. Using a surrogate model antigen, we
found that a cytoplasmic antigen is able to induce robust protective CD8 T-cell responses, but protein export further enhances
immunogenicity and protection. Our results show that a cytoplasmic localization does not exclude a protein’s candidacy for ma-
laria subunit vaccines and that protein secretion can enhance protective immunity.
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Multiple immunizations with live, attenuated, metabolicallyactive Plasmodium sporozoites remain the benchmark for
malaria vaccine development (1, 2). Recent clinical trials con-
firmed that repeated exposure to Plasmodium falciparum-infected
mosquitoes combined with treatment to suppress blood-stage
parasites confers sterile and lasting protection against malaria in a
human challenge model (3, 4). Likewise, intravenous administra-
tion of high doses of irradiation-attenuated, aseptic, purified, and
cryopreserved P. falciparum sporozoites can confer substantial,
even sterile, antimalarial immunity in humans (5). Experimental
vaccinations with irradiated sporozoites in murine models pro-
vided compelling evidence that sterilizing immunity is principally
mediated by CD8 T cells directed against liver-stage parasites
(6–8).
In one murine infection model, H-2d-restricted (BALB/c)
mice, protective immunity correlates with the magnitude of
CD8 T cells that recognize the Plasmodium circumsporozoite
protein (CSP) (9–11), but whether these responses contribute to
naturally acquired antimalarial immunity remains unresolved
(12). CSP is surface expressed on Plasmodium sporozoites, shed
during parasite transmigration of cellular barriers, and remains
detectable after hepatocyte invasion (13–15). Opsonization of
sporozoites inhibits CSP presentation by dendritic cells (DCs)
(16), possibly because the parasites are immobilized (17) and this
process interferes with T-cell priming. Immobilized heat-killed
parasites fail to induce a protective CD8 T-cell response (6, 18),
strongly suggesting that invasion of live parasites is central for
T-cell activation and protection. Mice with a tolerance for CSP
still develop protective immunity after immunization with irradi-
ated sporozoites, indicating that additional antigens contribute to
protection (19). Moreover, it has been shown that the sterile pro-
tection induced by immunization with irradiated sporozoites or
sporozoites under chloroquine prophylaxis is independent of CSP
(20, 21).
In the robust C57BL/6 (H-2b)/Plasmodium berghei vaccine and
infection model, CSP is not recognized by CD8 T cells, and the
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major sporozoite adhesin, thrombospondin-related anonymous
protein (TRAP), was identified as an immunodominant and pro-
tective antigen (22). Additional, hitherto unrecognized protective
antigens likely include preerythrocytic surface parasite proteins,
which are presented by DCs in the priming phase and by infected
hepatocytes to CD8 effector T cells, which in turn eliminate
liver-stage parasites (8, 23, 24).
A recent study showed that presentation of CSP that contained
the very potent H-2Kd ovalbumin (OVA) epitope to CD8 T cells
occurs by the two classical cellular pathways (16); during the
priming phase, DCs display the antigen by cross-presentation via
the endosomal pathway, whereas epitope presentation on infected
hepatocytes during the effector phase involves antigen secretion to
the host cell cytoplasm. Accordingly, DC priming in draining
lymph nodes and/or the spleen via phagocytosis is expected to
stimulate extensive T-cell responses to diverse secreted and non-
secreted parasite antigens, and antigen presentation to effector
CD8 T cells on major histocompatibility complex class I
(MHC-I) molecules of infected hepatocytes is much more re-
stricted. Sporozoite antigen presentation by DCs and hepatocytes
is TAP dependent, i.e., parasite molecules must reach the cyto-
plasm to be presented (16). Nevertheless, the mechanism of trans-
location of liver-stage-parasite protein into the hepatocyte cyto-
plasm and the entry into the MHC-I presentation pathway are
incompletely understood. Protein export is an important
parasite-mediated process to remodel an infected cell and typi-
cally involves a short, degenerate amino-terminal Plasmodium ex-
port element (PEXEL) (25–27). While this motif was initially re-
ported to be important for CSP translocation into the hepatocyte
cytoplasm (28), it was recently shown that it does not affect the
capacity of CD8 T cells to recognize and eliminate infected hepa-
tocytes (16).
Despite the recent progress in gaining a better understanding
of the molecular mechanisms of liver-stage immunity, it is unclear
whether recognition by effector CD8 T cells is restricted to
sporozoite surface antigens or extends to parasite proteins that are
synthesized during parasite development and exported to the host
hepatocyte. In support of the former notion, it has been proposed
that hepatocytes only present antigens that are secreted into the
cytoplasm after invasion or during cell traversal (29, 30). Recent
genome-wide immune profiling approaches in the two murine
models provided evidence for each of these propositions (22, 31).
Support for a striking immunodominance of sporozoite antigens
was reported for P. berghei/H-2b (C57BL/6) mice, which returned
two sporozoite-specific epitopes (22), while work in the Plasmo-
dium yoelii/H-2d (BALB/c) model identified a previously unrec-
ognized intracellular parasite protein that is highly unlikely to be
exported to the infected liver cell (31).
Here, we systematically analyzed the contribution of Plasmo-
dium preerythrocytic cytoplasmic and exported antigens to pro-
tection induced by vaccination with live attenuated sporozoites.
For this purpose, we generated two transgenic parasite lines that
express the OVA surrogate antigen with and without an export
targeting sequence. This approach allowed us to address the po-
tential role(s) of protein export in antigen presentation and prim-
ing of protective immune responses. Our findings support the
notion that exported antigens are presented by MHC-I molecules
more efficiently, resulting in superior T-cell activation and pro-
tection.
RESULTS
Generation of P. berghei OVA-expressing parasites. We first de-
termined to what extent the localization of P. berghei antigens in
infected cells affects MHC-I presentation. To this end, we gener-
ated a P. berghei parasite line that expresses a truncated version of
the OVA surrogate antigen, encompassing amino acids 142 to 389
and including the well-characterized CD8 and CD4 T-cell
epitopes. We placed OVA under the control of a preerythrocytic-
stage-specific promoter, UIS4 (15), and targeted a dispensable
P. berghei locus with an insertion vector to generate transgenic
OVA parasites (Fig. 1A; see also Fig. S1 in the supplemental ma-
terial). In addition, we generated the expOVA parasite line, which
expresses OVA fused to the CSP export sequence together with an
N-terminal PEXEL motif (22, 32), using the same strategy (Fig. 1A
and Fig. S1).
We confirmed that both transgenic OVA-expressing P. berghei
parasite lines were able to infect mosquitoes and mice similarly to
the parental parasite strain (see Fig. S2 in the supplemental mate-
rial). Since we observed no differences in either gliding motility
(data not shown) or in vivo infectivity, we conclude that the addi-
tional copy of the surrogate antigen expression cassette did not
affect the parasite’s life cycle progression or infection of mice.
Validation of surrogate antigen localization. To verify
whether the surrogate antigen was efficiently exported, we in-
fected Hepa 1-6 cells and examined them for the presence of OVA
using a specific antibody. As predicted, OVA was confined to the
parasite interior, while expOVA largely displayed a distinct pat-
tern on structures outside the parasite (Fig. 1B). The exported
OVA molecules were always surrounded by parasite membrane
material, as shown by positive staining for UIS4, a specific marker
of the parasitophorous vacuole membrane (PVM). We did not
detect the OVA signal free in the host cell cytoplasm but inside
vesicles, which are often detached from the PVM (32, 33). In con-
trast, the staining patterns of OVA parasites revealed the OVA
signal inside the parasite at all time points, and no OVA staining
was observed in the membranous structures extending into in-
fected cells (Fig. 1B). We also determined the expression levels of
OVA protein in both transgenic parasite cell lines (Fig. 1C). We
quantified the fluorescence levels by immunofluorescence assay
(IFA) in infected hepatoma cells and did not observe any differ-
ences between the parasite lines. Together, these data demonstrate
that the surrogate expOVA antigen is effectively exported into the
parasite’s liver-stage tubulovesicular network (LSTVN).
At late-liver-stage development, the OVA signal was very weak
(Fig. 1D), as expected for proteins expressed under the control of
the UIS4 promoter (15, 34). We therefore excluded the possibility
that OVA is present during blood infection. The OVA signal was
present in free sporozoites, in good agreement with the promoter
activity (Fig. 1E). Together, these findings show that the two trans-
genic lines differ in the spatial distribution but not the temporal
expression of the surrogate antigen OVA.
CD8 T-cell cytotoxicity in vivo does not depend on OVA
secretion. To interrogate whether OVA export is critical for anti-
gen presentation and T-cell activation in vivo, we determined the
cytotoxic activity of antigen-specific T cells isolated from mice
that were immunized with the two transgenic OVA parasite lines
(Fig. 2). Mice received 3  105 nonactivated, OVA-specific CD8
T cells (OT-1 cells) by intravenous (i.v.) injection. Next, mice were
i.v. immunized with 10,000 irradiation-attenuated normal or
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transgenic sporozoites. Six days later, the animals received 1  107
lymphocytes that were loaded with the SIINFEKL peptide and
labeled with a high concentration of carboxyfluorescein succin-
imidyl ester (CFSE) and 1  107 unloaded lymphocytes labeled
with a low concentration of CFSE (Fig. 2A). After 18 h, the spleens
were removed and the proportions of the two CFSE-labeled target
cell populations were determined by fluorescence-activated cell
sorting (FACS) analysis (Fig. 2B). To control for endogenous
T-cell activation, mice were immunized in the absence of OT-1
cell transfer (see Fig. S3 in the supplemental material). Control
mice and animals immunized with attenuated normal sporozoites
displayed a minor reduction of the target cell population (Fig. 2C
and Fig. S3). In contrast, attenuated transgenic OVA sporozoites
induced specific CD8 T-cell cytotoxicity, indicating that the sur-
rogate antigen was adequately processed and presented by MHC-I
molecules in vivo (Fig. 2C). Interestingly, both parasite popula-
tions induced a similar degree of T-cell-specific lysis.
Antigen export enhances CD8 T-cell proliferation in the
liver. Next, we evaluated CD8 T-cell proliferation in animals
infected with the two OVA-expressing parasite populations. To
this end, we transferred either 2  106 or 8  106 CFSE-labeled
OT-1 CD45.2 cells intravenously into CD45.1 C57BL/6 recipient
mice (Fig. 3A). One day, later, mice were immunized with 10,000
irradiation-attenuated normal and transgenic sporozoites.
FIG 1 Transgenic OVA and expOVA Plasmodium sporozoites and liver-stage parasites express and export the surrogate antigen ovalbumin (OVA). (A)
Schematic of transgenic P. berghei parasite lines that express a truncated version of the surrogate antigen OVA. The H-2b-restricted CD8 T-cell epitope
(SIINFEKL) and CD4 epitope (ISQAVAAHAEINEA) are highlighted in red and blue, respectively, in the schematic. Antigen expression is controlled by the
preerythrocytic-stage-specific UIS4 promoter. The expOVA parasites express OVA fused to an N-terminal protein export element (PEXEL), whereas OVA
parasites produce a cytoplasmic version of the antigen. (B) Indirect immunofluorescence microscopy of early liver-stage parasites (18 h after infection). (C)
Quantification of fluorescence signal revealed by IFAs of infected Hepa 1-6 cells at 24 h postinjection. Bars and whiskers show means  standard deviations.
Results are representative of two independent experiments (n  8). (D, E) Late liver-stage parasites (48 h after infection) (D) and P. berghei sporozoites (E).
Parasites were stained with a polyclonal anti-OVA antibody (red) and the nuclear dye Hoechst 33342 (blue). In addition, liver-stage parasites were stained with
an anti-P. berghei Hsp70 antibody (green). (B, D) To visualize the liver-stage tubulovesicular network (LSTVN), early liver-stage parasites were also stained with
an anti-PbUIS4 antiserum. Scale bars: 5 m (B, D); 2 m (E).
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Three days later, livers and spleens were harvested to recover
CD45.2 CD8 T cells (Fig. 3A) and quantify their CFSE intensity
(Fig. 3B). T-cell proliferation was measured by quantification of
CFSElow CD45.2 CD8 cells in these organs (Fig. 3C). In both
organs, CD8 T cells isolated from mice immunized with expOVA
parasites showed the highest proliferation. A substantial propor-
tion (~10 to 25%) of CD45.2 CD8 T cells recruited to the liver
proliferated upon infection with OVA sporozoites. This propor-
tion was significantly enhanced and reached up to ~40% in mice
infected with expOVA sporozoites. This difference was less pro-
nounced in the splenic CD45.2 CD8 T-cell population
(Fig. 3C). We did not detect any proliferation of OT-II (CD4) T
cells specific for ovalbumin by employing a similar strategy (data
not shown).
A cytoplasmic surrogate antigen stimulates IFN- secretion.
Since sterile protection induced by immunization with live
irradiation-attenuated sporozoites is associated with gamma in-
terferon (IFN-) secretion by proliferating CD8 T cells, we eval-
uated the ability of CD8 T cells to secrete IFN- after in vitro
restimulation with the SIINFEKL peptide. We transferred 3  105
nonactivated OT-1 cells into mice, and 24 h later, the recipient
animals were immunized with 10,000 irradiated normal or trans-
genic OVA sporozoites, followed by a second immunization
1 week later. CD8 T-cell responses were measured in both spleen
and liver 7 days after the last immunization (Fig. 4A) (22).
We observed that the IFN- levels in splenic and hepatic lym-
phocytes isolated from mice immunized with expOVA parasites
were higher than the levels in mice immunized with OVA para-
sites, although this difference was not significant, indicating that
antigen localization is not a major contributing factor to IFN-
secretion (Fig. 4A and B). As a control for T-cell restimulation, we
included the TRAP130 –138 peptide (amino acids 130 to 138 of
TRAP), which is an H-2b-restricted Plasmodium-specific immu-
noprotective epitope present in the thrombospondin-related
anonymous protein (TRAP) (22). The surface protein TRAP is
released by sporozoites during gliding motility, and it is also pres-
ent in liver-stage parasites. Lymphocytes isolated from the spleens
of mice immunized with OVA and expOVA-expressing parasites
showed high proportions of IFN- after restimulation with TRAP
peptide (Fig. 4B). Intriguingly, we observed a significant reduc-
tion of CD8 CD44 CD62L cells secreting TRAP-specific
IFN- in mice immunized with sporozoites expressing the surro-
gate antigen compared to the levels of these cells in mice immu-
nized with wild-type (WT) sporozoites; however, this reduction
was only significant for hepatic lymphocytes isolated from mice
immunized with OVA parasites (Fig. 4B). Finally, we note that the
magnitudes of CD8 CD44 CD62L cells secreting IFN- spe-
cific for endogenous (TRAP) and surrogate (OVA) differed in the
two organs (Fig. 4B). The TRAP responses were superior and in-
FIG 2 CD8 T-cell responses induced by intraparasitic and exported antigen
are cytolytic in vivo. (A) Schematic diagram of methodology. Mice received 3
 105 OT-1 cells and were either left untreated or immunized by i.v. injection
of 10,000 irradiated wild-type (WT), expOVA, or OVA sporozoites. Six days
later, target cells were prepared by pulsing syngeneic splenocytes with the
(Continued)
Figure Legend Continued
SIINFEKL or no peptide prior to labeling with CFSE and transfer to mice (1 
107 pulsed cells/mouse each). After 18 h, spleens of recipient mice were har-
vested and analyzed by CFSE fluorescence. (B) Representative histogram plots
showing the fate of target cells in naive mice (top left), mice immunized with
irradiated WT sporozoites (top right), and mice immunized with expOVA
(bottom left) or OVA (bottom right) sporozoites. (C) Quantification of in vivo
cytolytic activity. Bars and whiskers show means  standard deviations. *, P 
0.05 (Kruskal-Wallis test). Results are representative of one of two experi-
ments with three mice per group per experiment.
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FIG 3 Antigen export enhances CD8 T-cell proliferation in vivo. C57BL/6 CD45.1 mice received OT-1 cells as indicated in panel C; the cells were obtained from
CD45.2 donor mice and labeled with CFSE prior to transfer. After 18 h, mice received 10,000 irradiated WT, expOVA, or OVA sporozoites. Three days later,
spleens and livers were harvested from recipient mice and cells stained with CD8, CD3, CD45.1, and CD45.2 antibodies. (A) Representative histogram plots
showing the gating strategy for CD45.2 CD8 T cells. SSC, side scatter; FSC, forward scatter. (B) Representative histogram plots showing proliferation of hepatic
CD45.2 CD8 T cells from mice immunized with WT (left), expOVA (center), or OVA (right) sporozoites. (C) T-cell proliferation from livers and spleens of
sporozoite-immunized mice (n  3 each). Shown is the percentage of the CFSE population of OT-1 CD8 CD45.2 T cells originating from the liver (left) or
spleen (right). The amount of cells transferred is indicated. *, P  0.05 (Kruskal-Wallis test).
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FIG 4 IFN- production in CD8 T cells recognizing OVA and Plasmodium berghei sporozoite-derived antigens. (A) Mice were immunized weekly with two
doses of 10,000 irradiated P. berghei sporozoites. Seven days after the last immunization, cells from livers and spleens were tested for their capacity to produce
IFN- after restimulation in vitro with SIINFEKL peptide. As controls, splenic and hepatic cells were left unstimulated or stimulated with a sporozoite-specific
peptide, TRAP130 –138 (PbTrap130). Representative flow cytometry plots show IFN- production by CD8 T cells in spleens and livers of mice. (B) Percentages
of IFN- CD8 T cells are shown as means  standard deviations. Results are representative of two independent experiments (n  3 or 4 mice). *, P  0.05;
**, P  0.01 (Mann-Whitney test).
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ferior to OVA responses in the spleen and liver, respectively.
Taken together, these results suggest that cytoplasmic and surface
antigens can differ in their capacity to be presented in both organs.
Further experiments will be necessary to explain these observa-
tions.
Antigen export improves vaccine-induced protection. To ad-
dress the functional relevance of antigen-specific CD8 and
CD4 T cells to protection in this immunization and infection
model, we tested the contribution of OVA-specific T cells to inhi-
bition of Plasmodium liver-stage development in vivo. We trans-
ferred 2  105 nonactivated OT-I (CD8) and OT-II (CD4) T cells
each into mice, and 24 h later, immunized the recipient animals
with 10,000 irradiated normal or transgenic OVA sporozoites
(Fig. 5). Ten days later, the mice were challenged with the respec-
tive sporozoite lines used for immunization. Control mice did not
receive OVA-specific T cells before immunization.
In mice that received OT-1 T cells, we observed a very pro-
found reduction in parasite liver loads in those that were immu-
nized and challenged with expOVA sporozoites. In marked con-
trast, mice that received irradiated OVA or WT sporozoites
displayed similar degrees of reduction, which can be attributed to
endogenous protective antigens.
OT-II-cell-recipient mice treated with expOVA sporozoites
showed only modest reductions in liver loads compared to the
reductions in mice immunized and challenged with WT sporozo-
ites. Reductions were also apparent in comparison to the liver
loads in the mice immunized with OVA sporozoites, but the dif-
ference did not reach significance. To test whether CD4 T cells
play a helper role in CD8 T-cell-mediated protection in this
model, we next cotransferred 2  105 nonactivated OT-1 and
OT-II T cells each into mice and, 24 h later, immunized the recip-
ient animals with 10,000 normal or transgenic OVA sporozoites
(see Fig. S4 in the supplemental material). Ten days later, the mice
were challenged with the respective sporozoite lines used for im-
munization. A second cohort was treated similarly, but instead of
only one immunization, they received two immunizations with
irradiation-attenuated sporozoites (Fig. S4). As expected, mice
treated with irradiated WT sporozoites mounted a less effective
immune response, since the WT sporozoites cannot activate OT-1
and OT-2 cells. The reductions of parasite loads in livers of exp-
OVA sporozoite-immunized and -challenged mice were signifi-
cantly smaller than those in mice receiving OVA or normal sporo-
zoites and were more pronounced after the second immunization.
Taken together, these results indicate that antigen export is an
important factor for MHC-I antigen presentation. Furthermore,
OVA export does not improve antigen presentation by MHC-II,
suggesting that the CD4 T-cell contribution to protection is neg-
ligible in this model.
DISCUSSION
We generated reporter malaria parasites expressing a surrogate
antigen that either localizes to the parasite cytoplasm or is ex-
ported, allowing us to discriminate between cross-presentation of
phagocytized antigens and parasite-mediated antigen export. The
finding that live attenuated OVA and expOVA sporozoites were
both capable of efficiently inducing high levels of CD8 cytotoxic
T cells indicates that CD8 T-cell priming does not depend on the
antigen fate in the parasite. It is plausible that all cytoplasmic
antigens can be acquired via phagocytosis by antigen-presenting
cells (APCs), such as DCs or macrophages, and cross-presented to
specific T cells or presented directly to hepatocytes (30).
Intriguingly, our study revealed a marked difference in the pro-
liferation of CD8 T cells in the livers and spleens of mice that
received expOVA sporozoites. Previous work showed that presen-
tation of the endogenous sporozoite antigen CSP does not require
the protein export motif (16). Throughout intrahepatic develop-
ment, CSP is typically engulfed inside the PVM (14, 15, 35) but
can also be found in punctate structures in the host hepatocytes
during the early stages of infection (35, 36). We designed the ex-
pression of the surrogate antigen such that the protein abundance
increases after PVM formation, allowing us to distinguish be-
tween a cytoplasmic and an exported antigen. Therefore, our
model antigen differs fundamentally from the endogenous CSP
protein in that it is not released during transmigration. Moreover,
OVA is not part of the inner membrane complex (IMC) and,
hence, is not released into the host hepatocytes in early liver stages
after IMC dismantling. Therefore, this surrogate antigen model
depends on the presence of the engineered secretory and PEXEL
elements to be exported to the LSTVN (27). Our data suggest
greatly improved MHC-I presentation on infected hepatocytes
upon antigen export, leading to very efficient elimination of in-
fected cells by antigen-specific CD8 T cells. Therefore, we con-
clude that the antigen localization influences both the T-cell prim-
ing induced by irradiated sporozoites and the elimination of liver-
FIG 5 Immunization with expOVA sporozoites enhances protection against
reinfection. (A) Quantification of parasite liver loads in immunized mice that
received OT-1 or OT-2 cells. C57BL/6 mice received 2  105 OT-I (CD8) T
cells (OT-1) or OT-II (CD4) T cells (OT-2). Next, mice were immunized once
with 10,000 irradiated WT (black), expOVA (red), or OVA (green) sporozo-
ites. Control mice were immunized once without prior T-cell transfer.
Twelve days after the last immunization, animals were challenged by i.v. injec-
tion of 10,000 sporozoites of the corresponding genotype. After 42 h, livers
were removed and parasite loads were quantified by real-time PCR. Bars and
whiskers show means  standard deviations. *, P  0.05; **, P  0.01 (Mann-
Whitney test).
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stage parasites. It is tempting to speculate that during intrahepatic
development, the parasite tightly restricts the export of immuno-
genic proteins in order to minimize visibility by the immune sur-
veillance.
Candidate Plasmodium antigens for subunit vaccine develop-
ment are typically parasite surface proteins which mediate parasite
invasion of hepatocytes or red blood cells. High levels of circulat-
ing antibodies can reduce parasite motility and host cell invasion.
Thus, antibodies against sporozoite surface proteins can inhibit
sporozoite entry to the liver, contributing at least partially to pro-
tection (37). Sporozoite surface proteins are also released during
cell transit, upon either breaching of cellular barriers or transmi-
gration of hepatocytes (38) and, hence, constitute valid candidates
for presentation to effector CD8 T cells. It follows that this pro-
cess, as part of the parasite life cycle progression, could also serve
the purpose of distracting the immune system, for instance, by
directing antigen-specific T cells to traversed instead of infected
hepatocytes, but this hypothesis remains largely untested thus far.
One study that used spect sporozoites, which are defective in
cellular transmigration, reported that the activation of CSP-
specific CD8 T cells was markedly (~5-fold) reduced compared
to their activation by normal sporozoites (29). However, the con-
tribution of traversed cells to CD8 T-cell activation and parasite
killing was reported to be negligible (29). Thus far, prioritizing
antigens that can elicit potent T-cell-mediated immunity based on
parasite biology has been demanding.
Here, we addressed whether distinct targeting of an otherwise
identical surrogate antigen affects the magnitude of antigen-
specific T-cell responses. For this purpose, we expressed a nonsur-
face antigen under the control of a preerythrocytic-stage pro-
moter as a surrogate for a protective antigen. An attractive
hypothesis is that migrating expOVA sporozoites secrete the anti-
gen, which can then be acquired by nonparenchymal APCs and
cross-presented to T cells. This assumption would explain the
higher levels of CD8 T-cell proliferation in the livers and spleens
of mice immunized with attenuated expOVA parasites. However,
our attempts to detect OVA in trails deposited during parasite
gliding or inside cells after transmigration were unsuccessful
(G. N. Montagna, unpublished data).
Plasmodium sporozoites, unlike those of other protozoan
pathogens, such as Toxoplasma or Leishmania, do not infect pro-
fessional APCs and only invade and develop inside hepatocytes.
Apoptotic hepatocytes can be phagocytosed by DCs, but accord-
ing to in vitro studies, the number of infected apoptotic cells is not
sufficient for DC uptake and T-cell priming (39). It was postulated
that DCs could acquire parasite antigens from live infected hepa-
tocytes through phagocytosis or trogocytosis (40). Alternatively, it
has been suggested that infected hepatocytes can also directly
prime T cells in the liver (30). Unlike DCs, hepatocytes are ex-
pected to be more selective, since they can only present antigens
that have access to the cytoplasm. According to this model, OT-1
CD45.2 T-cell proliferation is expected to be elevated in mice
immunized with expOVA sporozoites due to more efficient
MHC-I presentation. This is in good agreement with our data. A
number of recent in vitro and in vivo studies have provided evi-
dence for direct T-cell stimulation by infected hepatocytes (30, 41,
42), and the role of hepatocytes in immune surveillance in the liver
clearly deserves further investigation (43).
Another important finding with potential implications for ma-
laria vaccine development is superior protection when the target
antigen contains a signal sequence and a PEXEL element. Two
recent imaging studies showed that Plasmodium-infected hepato-
cytes associate with CD8 T-cell clusters in vivo and in vitro, likely
correlating with parasite elimination (44, 45). Specific killing was
achieved by CD8 T cells that were specific for either the potent
H-2Kd-restricted CSP epitope (44) or the SIINFEKL peptide in a
cytoplasmic OVA molecule (45). In support of these studies, our
results suggest that an abundant antigen can contribute to im-
mune protection. Yet, we provide evidence that an exported anti-
gen improves the elimination of infected cells by antigen-specific
CD8 T cells.
Early studies showed that the protozoan Trypanosoma cruzi,
which has direct access to the host cell cytoplasm, releases proteins
that constitute the major source of MHC-I peptides for the gen-
eration of parasite-specific CTLs (46). In the case of apicomplexan
parasites, the PVM acts as a molecular sieve, which likely restricts
the transport of Plasmodium antigens to the host cell cytoplasm
(33, 47). In Toxoplasma-infected cells, antigens gain access to the
host cell cytoplasm, thus facilitating subsequent MHC-I presenta-
tion via fusion of the PVM with the host cell endoplasmic reticu-
lum (ER) (48). In marked contrast, the developing Plasmodium
liver-stage parasite does not appear to associate with the host ER
but develops an extensive and highly dynamic LSTVN, which as-
sociates with the late endosome/lysosome compartment (32).
This contact zone might serve as the entry point of Plasmodium
antigens, such as expOVA, to ultimately get access to MHC-I pre-
sentation via the lysosome and trans-Golgi network. This scenario
would differ markedly from the classical presentation pathway
reported for the sporozoite antigen CSP (16).
In conclusion, our findings suggest that abundant Plasmodium
liver-stage proteins that contain the PEXEL signature for protein
export and gain access to the PVM represent excellent candidates
for protective antigens. Our findings in Plasmodium are very con-
sistent with reports on the influence of antigen localization on
T-cell activation for other intracellular pathogens, including bac-
teria and protozoa (46, 49, 50). Further studies are warranted to
gain a better understanding of the cellular events that lead to the
entry of Plasmodium liver-stage antigens into the MHC class I
presentation machinery. These insights are important to under-
stand the escape mechanisms employed by the parasite to silence
potential immune responses during the crucial intrahepatic pop-
ulation expansion phase and, ultimately, for rational design of an
efficacious vaccine against malaria.
MATERIALS AND METHODS
Experimental animals. All animal work was conducted in accordance
with German Animal Protection Law (Tierschutzgesetz). The protocol
was approved by the ethics committees of the Max Planck Institute for
Infection Biology and the Regional Office for Health and Social Affairs,
Berlin, Germany (Landesamt für Gesundheit und Soziales Berlin: LAGeSo
Reg# G0469/09).
Plasmodium life cycle. For all experiments, P. berghei clone 507
(strain ANKA), which expresses green fluorescent protein (GFP) under
the constitutive EF1alpha promoter (51), was used. Parasites were main-
tained in NMRI mice. For mosquito transmission, mice were monitored
for high proportions of differentiated gametocytes and microgametocytes
capable of exflagellation. Anopheles stephensi mosquitoes were allowed to
blood feed for 15 min on anesthetized mice and maintained under a 14-h
light/10-h dark cycle in 75% humidity at 20°C. Mosquitoes were dissected
at days 10, 14, and 17 to determine infectivity, midgut sporozoite num-
bers, and salivary gland sporozoite numbers, respectively. To detect liver-
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stage parasites in hepatocytes, ~50,000 hepatoma (Hepa 1-6) cells were
seeded in 8-well chamber slides and grown to semiconfluence. P. berghei
sporozoites were added, incubated for 90 min at 37°C, and washed off.
After 18 or 48 h, infected cells were fixed with 4% paraformaldehyde
(PFA) and permeabilized with 1% Triton X-100, and parasites visualized
by using a primary antibody against P. berghei heat shock protein 70
(Hsp70) (52). To detect OVA, a commercial polyclonal antiserum was
used (C6534; Sigma-Aldrich). To visualize the parasite’s parasitophorous
vacuolar membrane (PVM), an antiserum against UIS4 of P. berghei
(PbUIS4) was used. Cells were fixed with 4% PFA and permeabilized with
1% Triton X-100. The IFA results were recorded with a Zeiss Axio Ob-
server.Z1 microscope (Zeiss) with a charge-coupled device camera
(AxioCam, Zeiss) using AxioVision software (Zeiss). The images were
processed with Photoshop, and fluorescence was quantified using FIJI
(ImageJ). To determine the prepatent period, which is defined as the time
to detection of the first parasites in the peripheral blood, 10,000 sporozo-
ites were injected intravenously into C57BL/6 mice and parasitemia as-
sayed by daily examination of Giemsa-stained blood films. For natural
transmission experiments, C57BL/6 mice were infected by 5 to 8 mos-
quito bites, and parasitemia was examined daily.
Recombinant protein expression and antiserum production. A
carboxy-terminal fragment of PbUIS4 encompassing amino acid residues
77 to 220 was fused to the amino terminus of the glutathione S-transferase
(GST) protein in the pGEX 1-lambda-T expression plasmid as described
previously (53). For the production of specific antiserum, 50 g of GST-
PbUIS4 suspended in phosphate-buffered saline (PBS) was injected intra-
peritoneally into male mice (NMRI). Two boosters of 10 g each were
given at days 15 and 25 postinjection, and 2 weeks after the second boost,
blood was collected and serum isolated. The specificity of the anti-PbUIS4
antiserum was evaluated by reactivity toward the His6-tagged version of
the protein.
Generation of OVA parasites. To generate P. berghei parasites ex-
pressing OVA, a 747-bp fragment of chicken OVA corresponding to
amino acids 142 to 389 was amplified with primers OVA_sin and OVA-
_rev, using an OVA-containing plasmid as the template (kindly provided
by Alexandra Lorenz, Deutsches Rheuma-Forschungszentrum, Berlin,
Germany). The UIS4 promoter was amplified from P. berghei genomic
DNA using primers UIS4_5’UTR_fd and UIS4_5’UTR_UIS4_PEXEL_
reverse. To amplify a 1.1-kb fragment of the P. berghei small subunit (ssU)
rRNA locus, primers PbSSU_fd and ssU_rv were used, with P. berghei
genomic DNA as the template. The resulting fragments were cloned into
the P. berghei transfection vector B3D, leading to plasmid pOVA-BD3.
For export of OVA, a 221-bp fragment from the PEXEL motif of CSP was
amplified using the primers PEXEL_fd and PEXEL_rv. The correspond-
ing OVA fragment was amplified using the primers OVA_fv2 and OVA-
_rev. The resulting fragments were cloned into B3D, generating plasmid
pexpOVA-BD3. Parasites were transfected with Apa1-digested pOVA-
BD3 and pexpOVA-BD3 plasmids by using the Nucleofector device
(Amaxa GmbH) and injected into naive mice. After transfection, recom-
binant parasite populations were selected using pyrimethamine (51).
Clonal parasite lines were obtained by limited dilution into 10 recipient
NMRI mice. Genotyping of recombinant parasite populations was per-
formed by PCR with the following primer combinations: Tg_pro and
OSssU_test_rev (test 1), OSssU_test_for and OVA_rev (test 2), OVA_fv2
and OVA_rev (test 3), and OSssU_test_for and ssU_rv (ssU rRNA). All
primers are listed in Table S1 in the supplemental material.
Cytolytic-T-cell assays. Spleen cells from transgenic OT-1 mice con-
taining 3  105 CD8 T cells isolated with CD8 (Lys2) microbeads
(Miltenyi Biotec) were transferred intravenously to C57BL/6 mice. After
24 h, mice were immunized with 10,000 irradiated sporozoites (OVA,
expOVA, and WT). At day 6 postimmunization, the in vivo cytotoxicity
assay was performed. To this end, splenocytes from female wild-type
C57BL/6 mice were incubated at 1  107 cells/ml in complete RPMI me-
dium alone (unpulsed cells) or 1  107 cells/ml with SIINFEKL peptide
(10 g/ml; pulsed cells) for 2 h. The cells were washed and incubated at 5
 107 cells/ml in the dark with CFSE (Molecular Probes Europe, Leiden,
Netherlands), either at 1.5 M (unpulsed cells; CFSElow) or 15 M
(peptide-pulsed cells; CFSEhigh), for 15 min at 37°C, washed again, and
resuspended in PBS at 1  108 cells/ml. Twenty million cells of a 1:1
mixture of the CFSElow/CFSEhigh target cells were adoptively transferred
into test mice, and 18 h later, the splenocytes of test mice were analyzed by
flow cytometry. The percentage of target cell killing was calculated using
the following formula: 100  (((% peptide-pulsed cells in immunized
mice/% unpulsed cells in immunized mice)/(% peptide-pulsed cells in
control mice/% unpulsed cells in control mice))  100).
T-cell proliferation assay. Spleen cells from transgenic OT-1 CD45.2
mice were isolated and labeled with CFSE according to the manufacturer’s
instructions (Molecular Probes). Amounts of 2  106 or 8  106 OT-1
CD45.2 cells were transferred intravenously to C57BL/6 CD45.1 mice.
After 24 h, the animals were immunized with 10,000 irradiated normal or
transgenic sporozoites. After 72 h, lymphocytes were isolated from
spleens and livers by using a Percoll gradient. The cells were resuspended
in PBS–2% bovine serum albumin buffer and stained with antibodies to
mouse CD8 (clone 53-6.7, peridinin chlorophyll protein [PerCP]; BD
Pharmingen), CD3 (clone 145-2C11, Pacific Blue; e-Bioscience), CD45.2
(clone 104, APC-780; e-Bioscience), and CD45.1 (clone A20, APC;
e-Bioscience). FACS analysis was performed in a BD LSRII flow cytome-
ter.
In vitro stimulation of immune cells and intracellular IFN- stain-
ing. For intracellular cytokine staining, single-cell suspensions at a density
of 2  106 cells per well were cultured in 96-well flat bottom plates in the
presence of TRAP130 –138 peptide (10 g/ml) or SIINFEKL peptide (10 g/
ml) and brefeldin A (1:1,000, GolgiPlug; BD Biosciences). After 5 h, sur-
face staining was performed using antibodies to CD3e (145-2C11, phyco-
erythrin [PE]-Cy7), CD62L (MEL-14, PE), CD8a (53-6.7, PerCP-Cy5.5),
and CD44 (IM7, Pacific blue) for 1 h on ice, washed twice in FACS buffer,
and fixed with 4% paraformaldehyde. Cells were permeabilized using BD
Perm/Wash buffer, which was also used throughout the staining proce-
dure. To detect intracellular IFN-, cells were stained with antibody to
IFN- (XMG1.2, APC) for 45 min. Cell acquisition was performed on a
BD LSRII flow cytometer, and data were analyzed using FlowJo software.
Quantification of parasite liver loads by real-time PCR. For quanti-
fication of parasite loads in the liver by real-time quantitative reverse
transcription (qRT)-PCR, C57BL/6 mice were challenged by intravenous
injection of 10,000 normal or transgenic sporozoites. Mice were sacrificed
42 h later, and livers removed and homogenized. Total RNA was isolated
with the RNeasy kit (Qiagen), and cDNA synthesized with the RETRO-
Script kit (Ambion). Real-time PCR was performed with the ABI 7500
sequence detection system and Power SYBR green PCR MasterMix (Ap-
plied Biosystems), using gene-specific primers for P. berghei 18S rRNA
(gi:160641) and mouse glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (gi:281199965) genes as described previously (54).
Statistical analysis. Statistical significance was assessed using the two-
tailed Student’s t test, Mann-Whitney test, and Kruskal-Wallis test. All
statistical tests were computed with GraphPad Prism 5 (GraphPad Soft-
ware).
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